Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)
- PMID: 40214958
- PMCID: PMC12181173
- DOI: 10.1007/s11357-025-01654-1
Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)
Abstract
Vascular contributions to cognitive impairment and dementia (VCID) represent a major public health challenge in the aging population, with age-related cerebromicrovascular dysfunction playing a critical role in its development. Understanding the mechanisms underlying cerebromicrovascular aging is crucial for devising strategies to mitigate this burden. Among the key hallmarks of aging, genomic instability and genetic heterogeneity have emerged as significant drivers of age-related diseases. Clonal hematopoiesis of indeterminate potential (CHIP) is a prominent manifestation of this instability, characterized by the non-malignant expansion of hematopoietic stem cell clones that harbor somatic mutations. CHIP is well-established as a contributor to atherosclerosis and cardiovascular disease through its promotion of chronic inflammation. Given that aging is also a major risk factor for cerebral small vessel disease (CSVD) and VCID, it is likely that the same aging processes driving large artery atherosclerosis in CHIP carriers also impair small vessels, including the cerebral microvasculature. While the role of CHIP in large vessel disease is well-documented, its specific contributions to cerebrovascular aging and microvascular dysfunction remain poorly understood. This review explores the potential role of CHIP in age-related cerebrovascular pathologies, with a particular focus on its contribution to CSVD. We discuss how CHIP-related mutations can promote inflammation and oxidative stress, potentially leading to endothelial dysfunction, dysregulation of cerebral blood flow (CBF), blood-brain barrier (BBB) disruption, microvascular inflammation, and cerebral microhemorrhages. Given the potential implications for VCID, elucidating these mechanisms is critical for developing targeted therapies aimed at reducing the burden of cognitive decline in aging populations. This review aims to highlight the current knowledge gaps and encourage further research into the intersection of CHIP, CSVD, and cognitive aging.
Keywords: Aging; Atherosclerosis; Blood–brain barrier; Cerebral blood flow; Cerebral hypoperfusion; Cerebral microhemorrhages; Cerebral small vessel disease; Cerebrovascular aging; Cognitive decline; Cognitive dysfunction; Endothelial dysfunction; Hematopoietic stem cells; Inflammaging; Inflammation; Microbleed; Microvascular dysfunction; Neurodegeneration; Neuroinflammation; Neurovascular coupling; Neurovascular unit; Oxidative stress; Stroke; VCI; Vascular aging; Vascular cognitive impairment and dementia; White matter hyperintensities.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: N/A Consent for publication: N/A. Conflict of interest: Dr. Hajnalka Andrikovics, Dr. Farzaneh Sorond, Dr. Andriy Yabluchanskiy, and Dr. Stefano Tarantini serve as Associate Editors for GeroScience. Dr. Zoltan Ungvari serves as Editor-in-Chief for GeroScience and has personal relationships with individuals involved in the submission of this paper.
Similar articles
-
Linking peripheral atherosclerosis to blood-brain barrier disruption: elucidating its role as a manifestation of cerebral small vessel disease in vascular cognitive impairment.Geroscience. 2024 Dec;46(6):6511-6536. doi: 10.1007/s11357-024-01194-0. Epub 2024 Jun 3. Geroscience. 2024. PMID: 38831182 Free PMC article. Review.
-
Cerebromicrovascular senescence in vascular cognitive impairment: does accelerated microvascular aging accompany atherosclerosis?Geroscience. 2025 Mar 21. doi: 10.1007/s11357-025-01621-w. Online ahead of print. Geroscience. 2025. PMID: 40113668 Review.
-
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2. Cochrane Database Syst Rev. 2022. PMID: 35833913 Free PMC article.
-
Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening.Geroscience. 2025 Jun;47(3):4871-4887. doi: 10.1007/s11357-025-01634-5. Epub 2025 Apr 2. Geroscience. 2025. PMID: 40169521 Free PMC article.
-
Transcriptomic profiling of senescence effects on blood-brain barrier-related gene expression in brain capillary endothelial cells in a mouse model of paclitaxel-induced chemobrain.Geroscience. 2025 Jun;47(3):3677-3691. doi: 10.1007/s11357-025-01561-5. Epub 2025 Feb 20. Geroscience. 2025. PMID: 39976844 Free PMC article.
References
-
- Dichgans M, Leys D. Vascular cognitive impairment. Circ Res. 2017;120:573–91. 10.1161/CIRCRESAHA.116.308426. - PubMed
-
- Girouard H, Munter LM. The many faces of vascular cognitive impairment. J Neurochem. 2018;144:509–12. 10.1111/jnc.14287. - PubMed
-
- O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol. 2003;2:89–98. 10.1016/S1474-4422(03)00305-3. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical